氯氮平联合帕利哌酮治疗70例难治性精神分裂症疗效观察

目的：探讨难治性精神分裂症患者行氯氮平联合帕利哌酮缓释片治疗的临床疗效.方法：将我院2010年3月-2013年12月接收的70例难治性精神分裂症患者随机分为观察组与对照组各35例,对照组行氯氮平治疗,观察组在其基础上施加帕利哌酮缓释片治疗,对比两组患者的临床疗效.结果：两组患者经治疗后,对照组治疗总有效率以62.9%明显不及观察组的85.7%;观察组治疗2周的PANSS评分后明显优于对照组;对照组不良反应发生率为25.7%,观察组为22.9%,组间差异比较无统计学意义（P〉0.05）.结论：难治性精神分裂症患者行氯氮平联合帕利哌酮缓释片治疗后的效果显著,值得推广.

Objective： To discuss the clinical effect of treating refractory schizophrenia with clozapine combining paliperidone. Methods： Choosed 70 cases of refractory schizophrenia from Mar. 2010 to Dec. 2013 to divide into study group and controlled group with 35 cases in each. The controlled group were treated with clozapine, the study group were treated with paliperidone added. Compared the effect of these two groups. Results： The total effective rate of controlled group was 62.9%, lower than 85.7% of study group. The PANSS scores of study group after treatment was better than controlled group. The incidence of adverse effects was 25.7%, had no difference with 22.9% of study group （P〉0.05）. Conclusion： Treating refractory schizophrenia with clozapine combining paliperidone is effective to extend in clinic.